Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uliledlimab + sintilimab + chemotherapy in NSCLC
NCT07005336Phase 2Active, not recruiting
- Sponsor
- TJ Biopharma
- Start
- Jan 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of uliledlimab in non-small cell lung cancer (NSCLC), sponsored by TJ Biopharma. Started Jan 2025; status: active, not recruiting.
02
Drugs
uliledlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07005336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07005336.